U.S. HIV Rapid Test Kits Market - Focused Insights 2023-2028

U.S. HIV RAPID TEST KITS MARKET INSIGHTS 

The U.S. HIV rapid test kits market was valued at USD 434.70 million in 2022 and is projected to reach USD 486.27 million in 2028, with a CAGR of 1.89% during the study period. The growth of the U.S. HIV rapid test kits market can be attributed to the high acceptance of HIV rapid test kits among people, high awareness of HIV infection, government support, and access to healthcare due to well-established healthcare infrastructure. 

MARKET DEFINITION  

The human immunodeficiency virus (HIV) rapid test kit is an in-vitro diagnostics (IVD) product that detects HIV exposure/presence in blood, oral fluid (saliva), and urine and yields results in 20-30 minutes. An HIV rapid self-test is a type of antibody test that can be used at home or in a private location. HIV rapid test kit is one of the convenient and widely accepted IVD products used for HIV diagnosis and preventive measures that are used in a home or any private place of the Individual. Three technologies are used to develop HIV rapid test kits that reduce the burden of laboratory visits and requirements. 

MARKET DRIVERS 

Increase in Targeted Patient Population: In 2021, WHO estimated that around 38.4 million people globally live with HIV. In 2021, approximately 2.0 million people in the U.S. lived with HIV. About 13% of these people were unaware and required testing. In 2019, an estimated 34,800 new HIV infections occurred in the U.S., according to CDC. 

Better Resource Availability & Funding for HIV Management: The UNAIDS Programme Coordination Board and the UNAIDS-associated country's governments, including the U.S. government, promise new investments to end HIV/AIDS globally. The increased resource availability and funding for HIV infection management accelerate the use of HIV care treatments, driving the adoption of HIV rapid test kits in the U.S.  

U.S. HIV RAPID TEST KITS MARKET HIGHLIGHTS 

• The rising prevalence of HIV infection in the area drives the demand for HIV rapid test kits. HIV self-testing awareness varies significantly between the U.S. and Canada, with the former much ahead. Government programs and financing to eliminate HIV by 2030 fuel this momentum and increase the distribution of HIV rapid test kits throughout the region. 
• In 2022, the U.S. accounted for a significant share of 97.32% of the North American HIV rapid test kits market due to higher HIV prevalence, awareness about the HIV status of the population, presence of global players, government support, and funding for HIV management. 
• Lateral Flow Immunoassay is growing significantly, with the fastest CAGR of 1.98% during the forecast period. Lateral flow immunoassay tests are growing as they provide immediate results. Lateral flow immunoassay tests are among the most common rapid diagnostic tests used in the market, and hundreds of millions of these tests are performed each year. 
• The blood sample type segment accounted for a major market share in the U.S. HIV rapid test kits market and dominated the other segments. Blood sample-based HIV rapid test kits are highly recommended by medical professionals due to their potential to carry HIV antibodies in high proportion. 
• The rise of 4th-generation and 5th-generation rapid test kits in the market has become more popular in the upcoming years. One of the leading market players, OraSure technologies, got approval for a home test kit known as OraQuick In-Home HIV Test (4th generation), which results in 20 to 40 minutes. 
• The online distribution segment is the fastest growing in the U.S. HIV rapid test kits market during the forecast period. The segment is growing because online channels will likely increase the purchase of HIV rapid test kits. Patients commonly choose online sales channels to buy HIV rapid test kits as they are available over-the-counter (OTC).

REGIONAL ANALYSIS  

The U.S. HIV rapid test kits market report contains exclusive data on 17 vendors. Abbott, OraSure Technologies, Bio-Rad Laboratories, ChemBio Diagnostics, and Biomerieux are the leading players in the U.S. HIV rapid test kits market. The market offers tremendous growth opportunities for existing and future/emerging players because of the awareness about the HIV status of the population.